Italy has had a national health service since 1978, to provide access to care to all citizens. The service uses 3-year plans to aim to meet demands and needs. The pharmaceutical sector is well developed with regard to R & D and production. Drug prices are fixed based on comparison prices in other European countries. Position within 3 classes of drugs determines the level of patient co-payment. Genetics have been recognized and included since 1996. Numerous recent events are likely to change the pharmaceutical sector, since recent regulations have not succeeded in reducing prices or utilization.
Pharmaceutical expenditure: Aspects of cost containment in Italy / L. Scalone, S. De Portu, P. Minghetti, L.G. Mantovani. - In: JOURNAL OF PHARMACEUTICAL FINANCE ECONOMICS & POLICY. - ISSN 1538-5396. - 12:4(2003), pp. 337-350. [10.1300/J371v12n04_06]
Pharmaceutical expenditure: Aspects of cost containment in Italy
P. MinghettiPenultimo
;
2003
Abstract
Italy has had a national health service since 1978, to provide access to care to all citizens. The service uses 3-year plans to aim to meet demands and needs. The pharmaceutical sector is well developed with regard to R & D and production. Drug prices are fixed based on comparison prices in other European countries. Position within 3 classes of drugs determines the level of patient co-payment. Genetics have been recognized and included since 1996. Numerous recent events are likely to change the pharmaceutical sector, since recent regulations have not succeeded in reducing prices or utilization.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.